Skip to main content
Top
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982–2006: a survey of patients aged ≥65 years

Authors: Mari Punab, Katrin Palk, Mirja Varik, Edward Laane, Hele Everaus, Erik Holmberg, Erik Hulegårdh, Lovisa Wennström, Soodabeh Safai-Kutti, Dick Stockelberg, Jack Kutti

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

Estonia regained independence in 1991 after five decades of occupation by the Soviet Union. The present population-based survey was carried out over five consecutive 5-year study periods (1982–2006) on the incidence and survival of de novo acute leukemia patients aged ≥65 years at diagnosis in Estonia and in a well-defined area in western Sweden. During the study period of retrospective work (1982–1996), the first 10 years were carried out while Estonia was still under the mentorship of the Soviet Union. Over these years, Estonian hematologists did not have access to therapeutic measures readily available to Swedish hematologists, and the results for survival for western Swedish patients with acute myeloid leukemia (AML) far exceeded those of their Estonian counterparts. However, the results for acute lymphoblastic leukemia were equally dismal in the two countries. Subsequent prospective population-based studies were carried out during the years 1997–2006. A gradual improvement as to long-term relative survival of the Estonian AML patients was observed. When studying 2002–2006, no difference as regards relative survival at 5 years was anymore present between the two countries. Over the first 20 years of our population-based studies, it was repeatedly observed that the age-standardized incidence rate particularly for de novo AML was considerably higher for the western Swedish as compared to the Estonian cohorts. During the last 5-year study period (2002–2006), no such difference between the two countries was present, indicating that some true changes in the reporting procedure in Estonia had occurred.
Literature
1.
go back to reference Wennström L, Juntikka E-L, Safai-Kutti S, et al. The incidence and survival of acute de novo leukaemias in Estonia and in a well defined region of western Sweden during 1982–1996: a survey of patients aged 16–64 years. Leuk Lymphoma. 2004;45:915–21.PubMedCrossRef Wennström L, Juntikka E-L, Safai-Kutti S, et al. The incidence and survival of acute de novo leukaemias in Estonia and in a well defined region of western Sweden during 1982–1996: a survey of patients aged 16–64 years. Leuk Lymphoma. 2004;45:915–21.PubMedCrossRef
2.
go back to reference Luik E, Palk K, Everaus H, et al. The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western Sweden during 1982–1996: a survey of patients aged ≥65 years. J Intern Med. 2004;256:79–85.PubMedCrossRef Luik E, Palk K, Everaus H, et al. The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western Sweden during 1982–1996: a survey of patients aged ≥65 years. J Intern Med. 2004;256:79–85.PubMedCrossRef
3.
go back to reference Wennström L, Safai-Kutti S, Stockelberg D, et al. The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997–2001: a survey of patients aged 16–64 years. Acta Haematol. 2011;126:176–85.PubMedCrossRef Wennström L, Safai-Kutti S, Stockelberg D, et al. The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997–2001: a survey of patients aged 16–64 years. Acta Haematol. 2011;126:176–85.PubMedCrossRef
4.
go back to reference Palk K, Luik E, Varik M, et al. The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997–2001: a survey of patients aged ≥65 years. Cancer Epidemiol. 2010;34:24–8.PubMedCrossRef Palk K, Luik E, Varik M, et al. The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997–2001: a survey of patients aged ≥65 years. Cancer Epidemiol. 2010;34:24–8.PubMedCrossRef
5.
go back to reference Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMed Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMed
6.
go back to reference Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–9.PubMed Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–9.PubMed
7.
go back to reference Öst Å, Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk Res. 1992;16:9–11.PubMedCrossRef Öst Å, Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk Res. 1992;16:9–11.PubMedCrossRef
8.
go back to reference Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302.PubMedCrossRef Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302.PubMedCrossRef
9.
go back to reference Juliusson G, Billström R, Gruber A, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20:42–7.PubMedCrossRef Juliusson G, Billström R, Gruber A, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20:42–7.PubMedCrossRef
10.
go back to reference Ahmad OE, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: a new WHO standard. GPE discussion paper series 31. Geneva: World Health Organization; 2001. Ahmad OE, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: a new WHO standard. GPE discussion paper series 31. Geneva: World Health Organization; 2001.
11.
go back to reference StatCorp. Stata statistical software: release 12. College Station, TX: StataCorp LP; 2012. StatCorp. Stata statistical software: release 12. College Station, TX: StataCorp LP; 2012.
12.
go back to reference The World Bank. The development report 1993: investing in health. New York: Oxford University Press; 1993.CrossRef The World Bank. The development report 1993: investing in health. New York: Oxford University Press; 1993.CrossRef
13.
go back to reference The World Bank. Estonia: the transition to a market economy. A World Bank country study. Washington: The World Bank; 1993. The World Bank. Estonia: the transition to a market economy. A World Bank country study. Washington: The World Bank; 1993.
14.
go back to reference Pierce N. Waste management challenges in Russia, Ukraine, and Estonia. Waste Age. 1993;24:194–202. Pierce N. Waste management challenges in Russia, Ukraine, and Estonia. Waste Age. 1993;24:194–202.
15.
go back to reference Micheli A, Coebergh JW, Mugeno E, et al. European health systems and cancer care. Ann Oncol. 2003;14(suppl 5):41–60.CrossRef Micheli A, Coebergh JW, Mugeno E, et al. European health systems and cancer care. Ann Oncol. 2003;14(suppl 5):41–60.CrossRef
16.
go back to reference Taylor PRA, Reid MM, Proctor SJ. Acute lymphoblastic leukemia in the elderly. Leuk Lymphoma. 1994;13:373–80.PubMedCrossRef Taylor PRA, Reid MM, Proctor SJ. Acute lymphoblastic leukemia in the elderly. Leuk Lymphoma. 1994;13:373–80.PubMedCrossRef
17.
go back to reference Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408–11.PubMedCrossRef Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408–11.PubMedCrossRef
18.
go back to reference Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008;93:594–600.PubMedCrossRef Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008;93:594–600.PubMedCrossRef
Metadata
Title
Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982–2006: a survey of patients aged ≥65 years
Authors
Mari Punab
Katrin Palk
Mirja Varik
Edward Laane
Hele Everaus
Erik Holmberg
Erik Hulegårdh
Lovisa Wennström
Soodabeh Safai-Kutti
Dick Stockelberg
Jack Kutti
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0487-x

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.